Form 4 for DXCM Dexcom
Accepted 2022-03-10 00:00:00 ET · period of report 2022-03-08 · accession 0001093557-22-000053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-03-10 | 2022-03-09 | DXCM | SAYER KEVIN R | COB, CEO, Pres, Dir | D - Sale to Iss | $406.06 | -9,985 | 107.7K | -8% | -$4.05M |
| 2022-03-10 | 2022-03-08 | DXCM | SAYER KEVIN R | COB, CEO, Pres, Dir | A - Grant | $0.00 | +16.3K | 110.9K | +17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-09 | D | D | 2,363 | $406.06 | 100,883 | D | — | — | (F3) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. |
| 2 | Common | Common Stock | 2022-03-09 | D | D | 4,473 | $406.06 | 103,246 | D | — | — | (F3) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. |
| 3 | Common | Common Stock | 2022-03-09 | D | D | 3,149 | $406.06 | 107,719 | D | — | — | (F3) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. |
| 4 | Common | Common Stock | 2022-03-08 | A | A | 16,251 | $0.00 | 110,868 | D | — | — | (F1) Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. (F2) Included in this number are 33,698 unvested restricted stock units, 16,251 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,963 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 8,484 of which were granted on March 8, 2020 and shall vest through March 8, 2023. |